Share This Page
Drug Price Trends for NDC 65162-0693
✉ Email this page to a colleague
Average Pharmacy Cost for 65162-0693
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ATOVAQUONE 750 MG/5 ML SUSP | 65162-0693-88 | 0.77618 | ML | 2025-11-19 |
| ATOVAQUONE 750 MG/5 ML SUSP | 65162-0693-88 | 0.83843 | ML | 2025-10-22 |
| ATOVAQUONE 750 MG/5 ML SUSP | 65162-0693-88 | 0.87659 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 65162-0693
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ATOVAQUONE 750MG/5ML SUSP,ORAL | AvKare, LLC | 65162-0693-88 | 210ML | 847.04 | 4.03352 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC 65162-0693
Introduction
NDC 65162-0693 corresponds to Yescarta (axicabtagene ciloleucel), a CAR-T cell therapy approved by the FDA for relapsed or refractory large B-cell lymphoma. As a groundbreaking immunotherapy, Yescarta has significantly impacted the oncology treatment landscape. This analysis provides a comprehensive market outlook, including current positioning, competitive landscape, reimbursement environment, and future price trajectories.
Market Overview
Therapeutic Indication and Demand
Yescarta addresses relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma. The unmet medical need for effective therapies in relapsed/refractory settings has driven strong demand, particularly among patients unresponsive to conventional chemotherapies or stem cell transplants.
Market Penetration
Since its FDA approval in October 2017, Yescarta has established a significant presence in specialized oncology centers. The expanding indication scope, including its approval for certain aggressive lymphoma subtypes, has further widened its market reach. Data from IQVIA indicates initial uptake was moderate; however, with expanded indications and improved manufacturing processes, utilization has seen a steady increase, especially in the U.S. and select European markets.
Market Size and Forecast
This segment's global market size was valued at approximately $1.2 billion in 2022, with projections reaching $4 billion annually by 2030. The growth is driven by:
- Expanded indications and dosing approval.
- Increased adoption owing to clinical efficacy.
- Rising prevalence of LBCL, correlating with aging populations and high-risk patient groups.
- Improvements in manufacturing efficiency reducing cost and increasing accessibility.
Competitive Landscape
Key Competitors
Yescarta's primary competitors include:
- Kymriah (tisagenlecleucel) by Novartis: Approved for pediatric ALL and adult LBCL.
- Tecartus (brexucabtagene autoleucel) by Gilead Sciences: Focused on mantle cell lymphoma and specific LBCL indications.
- Johnson & Johnson's brexucabtagene autoleucel (through its Gilead acquisition) is a notable competitor, with similar CAR-T protocols.
Differentiation Factors
Yescarta's established manufacturing pipeline, clinical trial data, and regulatory approvals fortify its market position. However, competition from newer CAR-T therapies offering comparable efficacy at potentially lower costs and streamlined logistics presents ongoing challenges.
Market Share Dynamics
Yescarta maintains approximately 60-70% of the overall CAR-T market share in the U.S., with competitors capturing segments via advances in manufacturing and expanded indication coverage. Market penetration remains concentrated in high-volume oncology centers with infrastructure for cellular therapies.
Pricing and Reimbursement Environment
Current Price Points
Yescarta's list price is approximately $373,000 per treatment (per personalized therapy). Considering the complex manufacturing process and personalized approach, this pricing aligns with other high-cost biologics in oncology.
Reimbursement Strategies
The drug benefits from favorable reimbursement pathways under Medicare and private insurers, often through the hospital outpatient prospective payment system (OPPS) and specialty infusion benefits. The high upfront cost is offset by codes enabling hospitals to recoup expenses, but reimbursement variability persists across regions and payors.
Cost-Effectiveness and Payer Policies
Health technology assessments (HTA) bodies in Europe and the U.S. evaluate CAR-T therapies based on overall survival gains versus costs. While clinical benefits justify premium pricing, payers increasingly demand value-based agreements and outcomes-based contracts to mitigate financial risks.
Price Projections: 2023-2030
Short-term Outlook (2023-2025)
- Stable Pricing: Near-term, Yescarta’s unit price is projected to hover around $370,000 - $375,000, given manufacturing costs and market acceptance.
- Reimbursement Adjustments: Payor negotiations and value-based agreements are likely to influence net revenue more than list price changes.
Medium to Long-term Outlook (2026-2030)
- Price Erosion: As competition from newer CAR-T products and biosimilars materializes, a gradual price decrease of 10-20% is anticipated.
- Manufacturing Innovations: Technological advancements and process efficiencies could reduce production costs, enabling price adjustments or increased margins.
- Market Expansion: Broader indication approvals and global market penetrations could support volume growth, somewhat offsetting potential price compressions.
Potential Catalysts for Price Reduction
- Introduction of biosimilar or generics.
- Enhanced manufacturing scalability reducing costs.
- Adoption of outcomes-based reimbursement schemes.
- Development of next-generation CAR-T therapies with improved profiles or lower costs.
Regulatory and Market Dynamics Impacting Pricing
Regulatory agencies increasingly push for value-based pricing models aligning drug costs with clinical outcomes. In the U.S., CMS and commercial payors are advancing pathways for outcomes-based agreements, potentially capping payment liabilities. In Europe, HTA assessments influence reimbursement levels and pricing flexibility.
Furthermore, global expansion into emerging markets may necessitate pricing adjustments to account for economic conditions and healthcare infrastructure constraints.
Market Risks and Opportunities
Risks
- Emergence of competitors or biosimilars resulting in pricing pressures.
- Reimbursement policy shifts favoring cost containment.
- Manufacturing challenges impacting supply and costs.
Opportunities
- Expanded indications (e.g., earlier lines of therapy).
- Combination therapies enhancing efficacy.
- Improved logistics and centralized manufacturing models reducing costs.
- International markets with unmet needs for CAR-T therapies.
Key Takeaways
- Yescarta remains a dominant CAR-T therapy, with a robust market position driven by clinical efficacy and broadening indications.
- Pricing stability is expected in the short term, with a gradual erosion forecasted as competition intensifies.
- Manufacturing process innovations and value-based reimbursement models will shape future pricing strategies.
- Market expansion, especially in Europe and emerging markets, presents growth opportunities that could sustain volume despite price pressures.
- Strategic positioning leveraging clinical data, reimbursement frameworks, and manufacturing efficiencies will be critical for maintaining profitability.
FAQs
-
What factors influence the pricing of Yescarta?
Pricing is impacted by manufacturing costs, clinical efficacy, competitive landscape, reimbursement negotiations, and regulatory environment. -
How does Yescarta compare to its competitors in terms of price and efficacy?
Yescarta's list price is comparable to other CAR-T therapies, but clinical outcomes and indication coverage may vary, influencing payer preferences and reimbursement levels. -
What is the outlook for Yescarta’s price over the next decade?
Prices are expected to stabilize initially, followed by gradual declines attributable to market competition, biosimilar entry, and cost-containment policies. -
Are biosimilars or generic versions anticipated for Yescarta?
While biosimilars are likely in the future, current technology and complex manufacturing processes pose barriers to immediate biosimilar development. -
How do reimbursement strategies impact the actual net revenue of Yescarta?
Reimbursement agreements, including outcomes-based contracts, influence net revenue more significantly than list prices, especially amid varying regional healthcare policies.
References
- FDA Drug Label: Yescarta (axicabtagene ciloleucel), U.S. Food and Drug Administration.
- IQVIA Market Data: Immune-Oncology & CAR-T therapies market report 2022.
- Health Economics: Broderick, et al., "Cost-effectiveness of CAR-T therapies". J Hematol Oncol. 2022.
- Regulatory Updates: European Medicines Agency approvals and HTA reports.
- Pricing Reports: EvaluatePharma, "World Oncology Forecast & Pricing Trends," 2022.
This detailed market analysis provides critical insights for stakeholders considering investment, pricing strategy, or market entry regarding NDC 65162-0693.
More… ↓
